Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTI-101 + SBRT in Pancreatic Cancer
NCT06141031Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2024
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tti-101 in pancreatic ductal adenocarcinoma (PDAC) (4 arms), sponsored by Washington University School of Medicine. Primary endpoint: Maximum tolerated dose and/or recommended phase II dose. Started Jan 2024; status: recruiting.
02
Drugs
tti-101
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06141031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06141031.